| Project/Area Number |
60570663
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | NIIGATA UNIVERSITY |
|---|
Principal Investigator |
TAKEDA Norio (1986) Niigata University, Brain Research Institute, Devision of Neurosurgery, 脳研究所, 助教授 (20150302)
吉田 誠一 (1985) 新潟大学, 医学部, 助手
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Ryuichi Niigata University, Brain Research Institute, Devision of Neurosurgery, 脳研究所, 教授 (30018816)
|
|---|
| Project Period (FY) |
1985 – 1986
|
| Project Status |
Completed (Fiscal Year 1986)
|
| Budget Amount *help |
¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1986: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1985: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | adoptive immunotherapy / Interleukine-2 / 抗腫瘍能 / malignant glioma / 悪性脳腫瘍患者 |
|---|
| Research Abstract |
We describe here the preliminary results of the local administration of antologous Lymphokine-activated killer (LAK) cells and the recombinant interleukin-2 (rIL-2) to the patients with malignant gliomas.
We treated 12 cases of malignant gliomas. The patients received both 1.8 to 21 x <10^8> LAK cells, and 8 to 16 x <10^4> units of rIL-2. Reduction of tumor size was observed in 4 patients. Improvement of symptoms was obtained in 7 of the 12 patients. No severe side effects occurred.
In the models of brain tumor-bearing rats, the local administration of LAK cells also seemed to be effective. Furthermore, activated killer cells, such as LAK cells, PHA-activated killer cells and their precursor cells were serologically studied for the recognition of their biological characteristics.
Further immunological study is required before its therapeutic value can be established.
|
